Skip to main content
PMC home page
Thrombosis Journal logoLink to Thrombosis Journal
. 2021 Nov 19;19:89. doi: 10.1186/s12959-021-00342-2

Impact of oral anticoagulation therapy on postoperative atrial fibrillation outcomes: a systematic review and meta-analysis

Mariana Fragão-Marques 1,2,3,✉, Francisco Teixeira 3, Jennifer Mancio 1,3, Nair Seixas 4, João Rocha-Neves 2,3, Inês Falcão-Pires 1,3, Adelino Leite-Moreira 1,2,3
PMCID: PMC8603521  PMID: 34798896

Abstract

Background

Post-operative atrial fibrillation (POAF) is the most common complication after cardiac surgery. Recent studies had shown this phenomenon is no longer considered transitory and is associated with higher risk of thromboembolic events or death. The aim of this study was to systematically review and analyze previous studies comparing oral anticoagulation therapy with no anticoagulation, regarding these long-term outcomes.

Methods

PubMed/MEDLINE, EMBASE, Web of Science and Cochrane Database were systematically searched to identify the studies comparing the risk of stroke, or thromboembolic events or mortality of POAF patients who received anticoagulation compared with those who were not anticoagulated. Incidence of stroke, thromboembolic events and all-cause mortality were evaluated up to 10 years after surgery. Time-to-event outcomes were collected through hazard ratio (HR) along with their variance and the early endpoints using frequencies or odds ratio (OR). Random effect models were used to compute statistical combined measures and 95% confidence intervals (CI). Heterogeneity was evaluated through Q statistic-related measures of variance (Tau2, I2, Chi-squared test).

Results

Eight observational cohort studies were selected, including 15,335 patients (3492 on Oral Anticoagulants (OAC) vs 11,429 without OAC) that met the inclusion criteria for qualitative synthesis. Patients had a wide gender distribution (38.6–82.3%), each study with a mean age above 65 years (67.5–85). Vitamin K antagonists were commonly prescribed anticoagulants (74.3–100%). OAC was associated with a protective impact on all-cause mortality at a mean of 5.0 years of follow-up (HR is 0.85 [0.72–1.01]; p = 0.07; I2 = 48%). Thromboembolic events did not differ between the two treatment arms (HR 0.68 [0.40–1.15], p = 0.15).

Conclusion

Current literature suggests a possibly protective impact of OAC therapy for all-cause mortality in patients with new-onset atrial fibrillation after cardiac surgery. However, it does not appear to impact thromboembolism rate.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12959-021-00342-2.

Keywords: Atrial fibrillation, Cardiac surgery, Anticoagulation, Long-term outcome

Introduction

Postoperative atrial fibrillation (POAF) is the most common complication after cardiac surgery, with a global incidence of 20–40%. Although its pathophysiologic mechanism is still uncertain, some progress has been made. Cardiac surgery is a stressful event which generates a chain of inflammatory reactions [1], with pro-inflammatory cytokines and increased oxidative stress. Such inflammation affects atrial conduction during atrial fibrillation by changing sodium channel function through the reduction of sodium currents and consequent upstroke velocity [2–4].

Moreover, one third of patients after coronary artery bypass grafting (CABG) and almost half of patients after valve repair/replacement (VR) develop atrial fibrillation after a cardiac procedure, usually occurring early in the recovery period [5, 6]. Although this arrhythmia was previously thought as transitory and benign, patients who develop the arrhythmia have longer intensive care unit hospitalizations, higher healthcare costs, and an increased risk of postoperative complications, namely stroke, thromboembolic events and mortality, both intrahospital and at 6 months [7–9].

While the relationship between short-term outcomes and POAF is well defined, only a few studies have demonstrated that POAF is associated with higher long-term stroke risk and mortality, contrasting to what was previously thought of POAF as a transitory and nonthreatening event [3, 10]. Indeed, surgical and anaesthetic techniques have improved over time, although patients are older and have a higher prevalence of comorbidities, possibly implying an increased structural left atrium remodelling [11–13]. Furthermore, evidence on anticoagulation therapy in this subgroup of patients is scarce, although some studies have analyzed the relationship of anticoagulation therapy in POAF management with the occurrence of adverse outcomes, namely thromboembolism and all-cause mortality [14–18]. Because of the older age of cardiac surgery patients, risks and benefits of OAC (Oral Anticoagulant) therapy should be carefully considered.

European guidelines for the management of atrial fibrillation are very clear and encourage the use of anticoagulation in AF patients for stroke prophylaxis [19]. Conversely, management of POAF is still a topic of debate in the scientific community. On one hand, 2014 AHA/ACA guidelines recommend the use of beta-blockers and nondihydropyridine calcium channel blockers, while ESC 2020 guidelines suggest amiodarone or vernakalant have been efficient in converting postoperative AF to sinus rhythm. On the other hand, the use of anticoagulation lacks good quality evidence, with no randomized clinical trials available and few observational studies. Thus, European guidelines leave the decision of anticoagulation therapy to the physician, while American guidelines (AHA/ACA) do not mention any course of action on this matter [20, 21].

The aim of this systematic review/meta-analysis was to investigate if the use of anticoagulation in patients who developed POAF undergoing cardiac surgery has an association with lower rates of long-term thromboembolic events, stroke, major bleeding and all-cause mortality; and to identify subgroups of POAF patients that can benefit more from OAC therapy.

Methods

The study protocol was registered in PROSPERO (PROSPERO ID: CRD42020208229) in accordance with standard reporting conventions. PRISMA guidelines were used in the writing of this manuscript.

Data sources and search strategy

A MEDLINE, EMBASE, Web of Science and Cochrane Database search was performed to find evidence up to the 5th August 2021 on stroke prevention with oral anticoagulants in patients who developed atrial fibrillation after cardiac surgery. The search query was constructed using the keywords “POAF”, “new onset postoperative atrial fibrillation”, “new onset atrial fibrillation”, “postoperative atrial fibrillation”, “anticoagulants” and “stroke”. The detailed search query is reported in supplementary materials (Table 1S).

Study selection

One reviewer independently screened search records for inclusion (FT) and another checked decisions (MFM). Titles and abstracts were screened at this stage and relevant studies were selected for full-text analysis. Inclusion criteria included randomized clinical trials and cohort studies on patients submitted to cardiac surgery who developed postoperative atrial fibrillation and received oral anticoagulation therapy versus no anticoagulation. Selected studies had to include stroke, a combined outcome including stroke (example: major adverse cardiovascular events (MACE), thromboembolic events), or all-cause mortality. Exclusion criteria included manuscripts in a language other than English, no full text available, duplicate manuscripts, and absence of outcomes of interest in the published manuscript.

Data extraction and quality assessment

Two reviewers (MFM, FT) blindly and independently checked the full texts, decided on the inclusion of individual studies and extracted data about study characteristics and event rates. Disagreements between reviewers were decided by the most senior reviewer. Extracted data included event rates of long-term 1) thromboembolism, a composite outcome of ischemic stroke, transient cerebral ischemia, and thrombosis or embolism in peripheral arteries; 2) stroke; 3) all-cause mortality; and 4) major bleeding. Estimates were presented as adjusted Hazard Ratios (HR) and respective 95% Confidence Intervals (CI).

Risk of bias was assessed by two blinded reviewers (MFM, FT), independently, using the Cochrane Risk Of Bias in Non-randomized Studies - of Interventions (ROBINS-I) tool (all selected studies were observational) [22]. Evaluated bias domains included bias due to confounding, selection bias, bias in classification of interventions, bias due to deviations from intended interventions, bias due to missing data, bias in measurement of outcomes and bias in selection of the reported result.

Data analysis

Assessment of reporting bias was performed with the Egger’s regression test and respective funnel plot. Heterogeneity was evaluated through Q statistic-related measures of variance (Tau2, I2, Chi-squared test), and a random-effects model with an inverse variance method was preferred to compute estimates for the summary effect. Forest plots were used to display results from the meta-analysis, where the measure of effect for each study is represented by a square and the respective areas are proportional to study weight.

A p value inferior to 0.05 was considered statistically significant for all analyses. Computations were conducted using Review Manager 5.3 and Stata 16.1.

Results

A total of 2890 records were identified through database searching, of which 1730 were kept after duplicates were removed. Thirty publications were assessed for eligibility through their full texts, with 8 manuscripts selected for qualitative synthesis. Two publications were excluded from quantitative analysis, since the number of patients and events was extremely low, with two additional studies excluded because their patient population was submitted to transcutaneous procedures (see below). Fig. 1 depicts the study selection process.

Fig. 1.

Fig. 1

Open in a new tab

Flowchart of the screening and selection process

Included research papers were published between 2010 and 2021, with a wide range of locations (Denmark, USA, South Korea, Poland, United Kingdom, Australia, Brazil, Italy, India). All papers were observational and based on a prospective cohort (Table 1). The total number of included patients with POAF for quantitative synthesis was 12,733 (2978 with Oral Anticoagulants (OAC) vs 9755 without OAC). Vitamin K antagonists represented the majority of prescribed oral anticoagulants across all studies (74.3–100%), although Yoon et al. 2019 lacked information concerning this issue [27].

Table 1.

Included studies in qualitative synthesis

First Author Year Country Patient Selection Study Design Anticoagulation POAF definition POAF (N) OAC vs No Anticoagulants Number Age Sex % (Males) Type of Surgery
CABG Valve CABG + Valve
Butt et al. [23] 2018 Denmark 1/1/2000–30/6/2015 Prospective Cohort 83.4% Warfarin AF rhythm requiring either medical therapy or cardioversion during hospitalization in patients without previous history of AF episodes 2108 Vitamin K or non-vitamin K antagonists 175 Median (IQR): 69.2 (63.7–74.7) 82.3 X
No anticoagulant 1527
Vora et al. [24] 2018 USA 01/11/2011–30/09/2015 Prospective Cohort 83.0% Warfarin New-onset AF following TAVR 1138 Oral Anticoagulant 329 Median (IQR): 85 (78–88) 38.6 TAVR
15.2% Factor Xa inhibitor
1.8% Dabigatran No anticoagulant 809
Butt et al. [25] 2019 Denmark 01/01/2000–30/06/2015 Prospective Cohort 97.6% Warfarin AF rhythm requiring either medical therapy or cardioversion during hospitalization in patients without previous history of AF 675 Oral Anticoagulant 420 Median (IQR): 71 (65–77) 59.3 Aortic and/or Mitral Valve Repair/ Replacement
No anticoagulant 255
El-Chami et al. [26] 2010 USA 1/1/1996–31/12/2007 Retrospective analysis of a Prospective Cohort 100% Warfarin Occurence of new-onset POAF or atrial flutter requiring treatment 2985 Warfarin 613 Mean ± sd: 67.5 ± 9.5 73 X
No anticoagulant 2375
Yoon et al. [27] 2019 South Korea 1/3/2010–1/2/2017 Prospective Cohort Warfarin or Novel Oral Anticoagulant Occurence of any episode of new-onset AF or flutter through hospitalization that lasted at least 30 s 31 Anticoagulant 11 Mean ± sd: 79.4 ± 5.0 52 TAVR
No anticoagulant 20
Taha et al. [28] 2020 Sweden 1/1/2007–31/12/2015 Prospective Cohort 86.2% Vitamin K antagonists POAF was defined as any new-onset atrial fibrillation during the first 30 postoperative days 7368 OAC 1770 Mean ± sd: 70 ± 8.0 81.5 X
No Anticoagulants 5598
Benedetto et al. [29] 2020 Poland, UK, Austria, Australia, Brazil, Italy, India 06/2004–12/2007 Post hoc analysis of a Randomized Controlled Multicenter Trial 100% Warfarin Occurence of any episode of AF or flutter (collectively called pAF for this analysis) after the index procedure through the time of discharge that lasted at least 30 s and was captured on a standard 12-lead ECG or cardiac telemetry 734 Warfarin 61 Mean ± sd: 66.41 ± 8.16 86,5 X
No Anticoagulant 662
Madsen et al. [30] 2021 Denmark 1999–2016 Retrospective cohort 74.3% Vitamin K antagonists AF within 30 days following STEMI 296 OAC therapy 113 Median (IQR): 71 (64–79) 69.9 PPCI
No Anticoagulant 183
First Author Follow-up time Thromboembolism Stroke All-cause Mortality CHA2DS2-VASc HAS-BLED Major bleeding Echocardiography data
OAC No OAC Left ventricle ejection fraction ≤ 30% n(%)
Butt et al. [23] Median (IQR) 5.1 (2.2–9.2) years HRa: 0.55 [0.32–0.95] – HRa: 1.09 [0.82–1.43] POAF: mean ± sd: 3.2 ± 1.4 POAF: mean ± sd: 2.2 ± 1.1 – –
Vora et al. [24] 1 year – HRa: 1.12 [0.67–1.89] HRa: 2.08 [1.56–2.78] POAF: median (IQR): 5 [5, 6] – HRa: 0.77 [0.61–0.98] 46 (4.0)
Butt et al. [25] Median (IQR) 4.2 (2.0–7.1) years HRa: 0.45 [0.22–0.90] – HRa: 0.64 [0.41–0.99] POAF: mean ± sd: 2.9 ± 1.7 Mean ± sd: 2.1 ± 1.2 Mean ± sd: 2.2 ± 1.2 – –
El-Chami et al. [26] Mean 6 years (range 0–12) – – HRa: 0.78 [0.66–0.92] – – – –
Yoon et al. [27] 12 months OR: 0.67 – – POAF: mean ± sd: 4.1 ± 1.4 – – 1 (3.2)
First Author Follow-up time Thromboembolism Stroke All-cause Mortality CHA2DS2-VASc HAS-BLED Major bleeding Echocardiography data
OAC No OAC OAC No OAC Left ventricle ejection fraction ≤ 30% n(%)
Taha et al. [28] 4.5 years (range 0–9) HRa: 1.01 [0.77–1.33] HRa: 1.08 [0.80–1.45] HRa: [0.73–1.09] ≥2 n(%) 1637 (95.5) n(%) 5201 (94.2) – – HRa: 1.40 [1.08–1.82] –
≥4 n(%) 925 (54.0) n(%) 2738 (50.3)
Benedetto et al. [29] 10 years – Cumulative incidence (OAC): 3.6% [95% CI 0.0–8.4%] – POAF: mean ± sd: 3.46 ± 1.31 – – Cumulative Incidence (OAC): 3.4 [95% CI 0.0–8.1] 21 (2.9)
Cumulative incidence (No OAC): 5.3% [95% CI 3.5–7.0%] Cumulative Incidence (No OAC): 4.1 [95% CI 2.6–5.7]
Madsen et al. [30] Median (IQR) 4.7 (2.8–7.4) years – HRa: 0.70 [0.33–1.49] HRa: 0.69 [0.47–1.00] ≥2 n(%) 105 (92.9%) n(%) 169 (92.4%) ≥3: n(%) 77 (68.1) ≥3: n(%) 92 (50.3) HRa: 1.31 [0.75–2.27] –
Open in a new tab

HRa adjusted Hazard Ratio with 95% Confidence Intervals

While POAF definitions included only new-onset episodes, Vora et al. 2018 and Yoon et al. 2019 considered all cases of POAF, in contrast with the remaining studies, which exclusively selected episodes requiring treatment. All studies had a mean age above 65 years (67.5–85), even though gender distribution varied significantly across studies (38.6–82.3% of males), with male gender being more common in CABG surgery. Selected research papers included both CABG [23, 26] and valve repair/replacement [24, 25, 27].

Risk of bias is represented in Fig. 1S and Fig. 2S (supplementary content). Yoon et al. 2019 presented their results as a percentage of events between therapeutic groups, without an adjusted measure of effect or an adequate time-dependent analysis. In the OAC group, there was no description of which specific anticoagulants were used and only 2 thromboembolic events were reported. Thus, this study was considered as having a serious risk of bias and was excluded from quantitative analysis. Benedetto et al. 2020 is a post-hoc analysis of a well-designed randomized clinical trial, although it did not present time-dependent adjusted estimates; thus, this study was not included in the quantitative synthesis and had a serious risk of bias in domain 1, thus presenting an overall serious risk of bias. The remaining studies had a moderate risk of bias due to confounding, as all measures of effect were adjusted (see below), despite not being randomized controlled trials. The selected papers for quantitative synthesis all had time-dependent adjusted estimates and were exclusively from cohorts submitted to conventional cardiac surgery (Vora et al. and Madsen et al. were excluded). Moreover, considering papers with more than one reported outcome, Butt et al. 2018 and Butt et al. 2019 had into account competing risks in their outcome analysis. Taha et al. 2020, on the other hand, does not clarify this potential source of confounding.

Furthermore, there was little information concerning deviations from intended interventions or missing data. However, Butt et al. 2019 reported a decrease to 55.0% at 3 months of patients who were initially in the OAC treatment arm, to 31.7% at 6 months and 22.1% at 1 year of follow-up, being attributed a serious risk of bias concerning deviations from intended treatment. Benedetto et al. 2020 and El Chami et al. 2010 used multiple imputation to eliminate missing values, the latter considering absent data as missing at random; thus, a low risk of bias was considered in these cases. Apart from Yoon et al. 2019, all selected studies were classified as having an overall moderate risk of bias.

All-cause mortality

All-cause mortality was reported in all selected studies for quantitative analysis. The median or mean follow-up varied between 4.2–6 years and the pooled HR is 0.85 [0.72–1.01] (p = 0.07; I2 = 48%), with 2978 vs 9755 (OAC vs control) analyzed patients (Fig. 2). Covariates used in the adjusted model are presented in Table 2S.

Fig. 2.

Fig. 2

Open in a new tab

Pooled estimate of all-cause mortality with OAC therapy

Publication bias

Publication bias for this outcome was evaluated by a funnel plot and Egger’s regression test (p = 0.85), which suggests absence of bias – Fig. 3.

Fig. 3.

Fig. 3

Open in a new tab

Funnel plot and Egger’s regression test

Thromboembolism

Thromboembolism was reported in 3 of the selected studies [23, 25, 28] and was defined as a composite of ischemic stroke, transient cerebral ischemia, and thrombosis or embolism in peripheral arteries in all the research papers (Table 3S). A total of 2365 vs 7380 (OAC vs control) patients were included in the analysis and median follow-up time varied between 4.2–5.1 years. HR and 95% CI were adjusted for comorbidities and other concomitant medical therapy (Table 2S). The pooled estimate was HR 0.68 [0.40–1.15] (p = 0.15; I2 = 72%) and the respective forest plot is represented in Fig. 4.

Fig. 4.

Fig. 4

Open in a new tab

Pooled estimate of thromboembolism event with OAC therapy

Stroke

Stroke was reported as a separate outcome in 3 studies – Madsen et al. (Primary Percutaneous Coronary Intervention - PPCI), Taha et al. (CABG) and Vora et al. (Transcatheter Aortic Valve Replacement - TAVR). The results were similar between studies, with no reported impact of OAC on stroke rates (Madsen et al. HR 0.70 [0.33–1.48]; Taha et al. HR 1.08 [0.80–1.46]; and Vora et al. HR 1.12 [0.67–1.87]). Table 2S presents the covariates included in each study’s multivariate cox regression.

Major bleeding

This outcome was reported in 3 of the included studies (Madsen et al., Taha et al. and Vora et al.), with conflicting results between publications. Taha et al. found an association between OAC therapy and major bleeding (HR 1.40 [1.08–1.81]), with Madsen et al. reporting no significant impact of OACs in bleeding events (HR 1.31 [0.75–2.29]). However, Vora et al. reported a protective effect of this therapy – HR 0.77 [0.61–0.97]. The covariates used in each of the 3 studies are present in Table 2S and the respective definitions for major bleeding are in Table 3S.

Discussion

In this meta-analysis, POAF patients treated with OACs appear to have a reduction in long-term all-cause mortality (p = 0.07, non-significant). Furthermore, these patients had a tendency towards a reduction in risk of long-term thromboembolic events (p = 0.15).

This work combined the available research papers on OAC therapy, resulting in estimates with a high number of patients (12,733 in total) corresponding to high-quality observational studies. AF has long been implicated in the incidence of stroke, with a fivefold increase in risk of ischemic stroke, namely, cardioembolic, which has particularly high mortality and residual disability [31]. Cryptogenic strokes may have AF as an underdiagnosed underlying cause, as demonstrated by monitoring with an insertable cardiac monitor in a randomized controlled trial [32]. In addition to stroke, prevention of systemic thromboembolic events is part of the fundamental management of AF [33]; AF represents a significant cause of mortality, with increasing incidence due to aging demographics [4, 34]. As far as AF management is concerned, anticoagulation therapy with vitamin K antagonists (VKA) reduces stroke and mortality by 64 and 26%, respectively [35]. On the other hand, the novel oral anticoagulants (NOAC) are a reasonable alternative for thromboembolic event prevention in non-valvular AF, with a 19% reduction in risk of stroke/systemic embolism, and 51% reduction in haemorrhagic stroke when compared with VKAs [36].

Nevertheless, paroxysmal AF classification remains elusive, with diverse patterns possibly requiring and presenting different treatments and outcomes [7, 37]. POAF is a subtype of paroxysmal AF linked to increased early stroke and 30-day mortality risk [38]. Concerning long-term results, POAF is associated with an increased risk of stroke and mortality, as demonstrated in a meta-analysis of patients submitted to both cardiac and noncardiac surgery, where the latter presented a higher risk of stroke when compared to cardiac surgery. These patients presented a 37% increase in risk of both long-term stroke and mortality [39]. In this work, OAC therapy appears to prevent long-term mortality (p = 0.07, non-significant), with a tendency to reduce long-term thromboembolic events (p = 0.15).

It is necessary to further understand if short and long POAF episodes present the same stroke risk, and if they benefit in a similar way from OAC therapy. Similarly, there is no evidence in which type of anticoagulation therapy should be used, as all research papers considered OAC therapy without discriminating NOAC vs VKA. Currently, guidelines recommend considering the overall presence of stroke and bleeding risk factors, although the definition of AF burden at which to initiate OAC therapy is poorly defined, and consequently, this knowledge gap results in significant variation in clinical practice [34, 40]. In this meta-analysis, bleeding risk varied between heterogeneous studies, which could be related both to the underlying disease (coronary artery disease or valvular disease) and to the type of procedure (CABG, PPCI or TAVR).

Thromboembolic events are one of the most serious complications of AF, and without anticoagulation therapy, stroke occurrence varies between 1.9 and 18.2%, depending on comorbidities [41]. The potential decrease in mortality in OAC-treated POAF patients could be related to cardiovascular events. Additionally, POAF is a risk factor for AF occurrence at follow-up, which could also help to explain these findings [41]. However, thromboembolism risk was not decreased significantly with OAC-therapy. Main causes of mortality in AF could be not only thromboembolic events but also heart failure (either ischemic or valvular) and bleeding due to anticoagulation therapy. The overall measure of effect (hazard ratio) in all-cause mortality was 0.85 [0.72–1.01] vs 0.68 [0.40–1.15] in thromboembolism. There were less studies reporting thromboembolism, with the ones reporting it, presenting estimates with greater standard errors, resulting in a larger confidence interval for thromboembolism when compared with all-cause mortality - [0.40–1.15] vs [0.72–1.01]. In addition, there could be a degree of under reporting of thromboembolic events when compared to mortality. Acute myocardial infarction is also a possible cause of death in these patients which was not included in the thromboembolism outcome (composite of ischemic stroke, transient cerebral ischemia, and thrombosis or embolism in peripheral arteries) [42]. These factors could have contributed to the discrepancy in results concerning all-cause mortality and thromboembolic events.

This systematic review and meta-analysis focused on different types of cardiac surgery with a relatively low number of studies, therefore increasing heterogeneity, despite including a high number of patients. Two of the manuscripts were from the same database, even though included patients were submitted to different types of surgery, limiting generalizability, counterbalanced by the wide range of locations (Denmark, USA, South Korea, Sweden, Poland, UK, India, Austria, Australia, Brazil, Italy). As all selected papers were observational, there is a risk of indication bias. Still, pooled estimates were adjusted for a vast number of covariates. Deviation from intended interventions was reported in three studies, with only one reporting a significant deviation in the treatment arm over time, which was accounted for in the statistical analysis [25]. Furthermore, Taha et al. did not have competing risks into account in their analysis, which could be a source of bias. Finally, although the estimates were adjusted, each study had a different pool of covariates in their regression models, increasing heterogeneity.

Conclusions

Current literature suggests a possibly protective impact of OAC therapy for all-cause mortality in patients with new-onset atrial fibrillation after cardiac surgery. However, it does not appear to impact stroke, thromboembolism and major bleeding.

Supplementary Information

12959_2021_342_MOESM1_ESM.docx (554.1KB, docx)

Additional file 1. Supplementary Methods and Results.

Acknowledgements

Not applicable.

Abbreviations

AF

Atrial Fibrillation

AHA/ACA

American Heart Association/American College of Cardiology

POAF

Post-Operative Atrial Fibrillation

CABG

Coronary artery bypass grafting

CI

Confidence Intervals

ESC

European Society of Cardiology

FT

Francisco Teixeira

MACE

Major Adverse Cardiovascular Events

MFM

Mariana Fragão-Marques

NOAC

Novel Oral Anticoagulants

OAC

Oral Anticoagulants

OR

Odds Ratio

PPCI

Percutaneous Coronary Intervention

TAVR

Transcatheter Aortic Valve Replacement

VKA

Vitamin K Antagonists

VR

Valve repair/replacement

Authors’ contributions

Conceptualization and design, MFM; Methodology, MFM, FT and JM; Analysis, MFM and FT; Data acquisition, MFM and FT; Original draft preparation, MFM and FT; Review and editing, JM, JRN, NS, ALM, IFP; Project administration, MFM. All authors have read and agreed to the published version of the manuscript.

Funding

This study was supported by the Cardiovascular R&D Center, financed by national funds through FCT—Fundação para a Ciência e Tecnologia, I.P., under the scope of the projects UID/IC/00051/2019 and UIDP/00051/2020, and European Regional Development Fund (ERDF) through Compete 2020–Programa Operacional Competitividade E Internacionalização (POCI), the project DOCNET (Norte-01-0145-FEDER-000003), supported by Norte Portugal regional operational programme (Norte 2020), under the Portugal 2020 partnership agreement, through the European Regional Development Fund (ERDF), the project NETDIAMOND (POCI-01-0145-FEDER016385), supported by European Structural And Investment Funds, Lisbon’s regional operational program 2020.

Availability of data and materials

All data generated and analyzed are included in this research article.

Declarations

Ethics approval and consent to participate

The authors have obtained ethical approval to participate.

Consent for publication

Not applicable.

Competing interests

There are no competing interests.

Footnotes

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Racca V, Torri A, Grati P, Panzarino C, Marventano I, Saresella M, et al. Inflammatory Cytokines During Cardiac Rehabilitation After Heart Surgery and Their Association to Postoperative Atrial Fibrillation. Sci Rep 2020;10(1) 8618. [DOI] [PMC free article] [PubMed]
  • 2.Ishii Y, Schuessler RB, Gaynor SL, Yamada K, Fu AS, Boineau JP, et al. Inflammation of Atrium After Cardiac Surgery Is Associated With Inhomogeneity of Atrial Conduction and Atrial Fibrillation. Circulation. 2005;111(22):2881. doi: 10.1161/CIRCULATIONAHA.104.475194. [DOI] [PubMed] [Google Scholar]
  • 3.Wang GK, Wang SY. Modifications of Human Cardiac Sodium Channel Gating by UVA Light. J Membr Biol. 2002;189(2):153. doi: 10.1007/s00232-002-1010-z. [DOI] [PubMed] [Google Scholar]
  • 4.Proebstle T, Mitrovics M, Schneider M, Hombach V, Rüdel R. Recombinant interleukin-2 acts like a class I antiarrhythmic drug on human cardiac sodium channels. Pflügers Archiv Eur J Physiol. 1995;429(4):462. doi: 10.1007/BF00704150. [DOI] [PubMed] [Google Scholar]
  • 5.Seo C, Michie C, Hibbert B, Davis DR. Systematic review of pre-clinical therapies for post-operative atrial fibrillation. PLoS One. 2020;15(11):e0241643. doi: 10.1371/journal.pone.0241643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Fragão-Marques M, Mancio J, Oliveira J, Falcão-Pires I, Leite-Moreira A. Gender differences in predictors and long-term mortality of new-onset postoperative atrial fibrillation following isolated aortic valve replacement surgery. Ann Thoracic Cardiovasc Surgery. 2020;26(6):342–351. doi: 10.5761/atcs.oa.19-00314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Creswell LL, Schuessler RB, Rosenbloom M, Cox JL. Hazards of postoperative atrial arrhythmias. Ann Thorac Surg. 1993;56(3):539. doi: 10.1016/0003-4975(93)90894-N. [DOI] [PubMed] [Google Scholar]
  • 8.Eikelboom R, Sanjanwala R, Le M-L, Yamashita MH, Arora RC. Postoperative Atrial Fibrillation After Cardiac Surgery: A Systematic Review and Meta-analysis. Ann Thorac Surg. 2020. [DOI] [PubMed]
  • 9.Shen J, Lall S, Zheng V, Buckley P, Damiano RJ, Schuessler RB. The persistent problem of new-onset postoperative atrial fibrillation: A single-institution experience over two decades. J Thorac Cardiovasc Surg. 2011;141(2):559. doi: 10.1016/j.jtcvs.2010.03.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Lin MH, Kamel H, Singer DE, Wu YL, Lee M, Ovbiagele B. Perioperative/Postoperative Atrial Fibrillation and Risk of Subsequent Stroke and/or Mortality: A Meta-Analysis. Stroke. 2019;50(6):1364–1371. doi: 10.1161/STROKEAHA.118.023921. [DOI] [PubMed] [Google Scholar]
  • 11.Fragão-Marques M, Miranda I, Martins D, Barroso I, Mendes C, Pereira-Neves A, et al. Atrial matrix remodeling in atrial fibrillation patients with aortic stenosis. BMC Cardiovasc Disord. 2020;20(1):468. doi: 10.1186/s12872-020-01754-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Pessoa-Amorim G, Mancio J, Vouga L, Ribeiro J, Gama V, Bettencourt N, et al. Impaired Left Atrial Strain as a Predictor of New-onset Atrial Fibrillation After Aortic Valve Replacement Independently of Left Atrial Size. Revista Española de Cardiología (English Edition) 2018;71(6):466–476. doi: 10.1016/j.rec.2017.10.005. [DOI] [PubMed] [Google Scholar]
  • 13.Fragão-Marques M, Saraiva F, Oliveira J, Lourenço AP, Leite-Moreira A, Falcão-Pires I. De novo atrial fibrillation following aortic valve replacement surgery is associated with decreased creatinine clearance and increased C-reactive protein levels. Porto Biomed J. 2017;2(5):189. doi: 10.1016/j.pbj.2017.07.034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Butt JH, Olesen JB, Gundlund A, Kümler T, Olsen PS, Havers-Borgersen E, et al. Long-term Thromboembolic Risk in Patients with Postoperative Atrial Fibrillation after Left-Sided Heart Valve Surgery. JAMA Cardiol. 2019;4(11):1139–1147. doi: 10.1001/jamacardio.2019.3649. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Butt JH, Xian Y, Peterson ED, Olsen PS, Rørth R, Gundlund A, et al. Long-Term thromboembolic risk in patients with postoperative atrial fibrillation after coronary artery bypass graft surgery and patients with nonvalvular atrial fibrillation. JAMA Cardiol. 2018;3:417–424. doi: 10.1001/jamacardio.2018.0405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Mariscalco G, Klersy C, Zanobini M, Banach M, Ferrarese S, Borsani P, et al. Atrial Fibrillation After Isolated Coronary Surgery Affects Late Survival. Circulation. 2008;118(16):1612. doi: 10.1161/CIRCULATIONAHA.108.777789. [DOI] [PubMed] [Google Scholar]
  • 17.Horwich P, Buth KJ, Légaré J-F. New Onset Postoperative Atrial Fibrillation is Associated with a Long-Term Risk for Stroke and Death Following Cardiac Surgery. J Card Surg. 2013;28(1):8. doi: 10.1111/jocs.12033. [DOI] [PubMed] [Google Scholar]
  • 18.Gialdini G, Nearing K, Bhave PD, Bonuccelli U, Iadecola C, Healey JS, et al. Perioperative Atrial Fibrillation and the Long-term Risk of Ischemic Stroke. JAMA. 2014;312(6):616. doi: 10.1001/jama.2014.9143. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020;29. [DOI] [PubMed]
  • 20.Fuster V, Rydén LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, et al. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. Circulation. 2001;104(17):2118. doi: 10.1161/circ.104.17.2118. [DOI] [PubMed] [Google Scholar]
  • 21.Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893. doi: 10.1093/eurheartj/ehw210. [DOI] [PubMed] [Google Scholar]
  • 22.Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. doi: 10.1136/bmj.i4919. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Butt JH, Xian Y, Peterson ED, Olsen PS, Rørth R, et al. Long-Term thromboembolic risk in patients with postoperative atrial fibrillation after coronary artery bypass graft surgery and patients with nonvalvular atrial fibrillation. JAMA Cardiol. 2018;3(5):417–424. doi: 10.1001/jamacardio.2018.0405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Vora AN, Dai D, Matsuoka R, Harrison JK, Hughes GC, Sherwood MW, et al. Incidence, Management, and Associated Clinical Outcomes of New-Onset Atrial Fibrillation Following Transcatheter Aortic Valve Replacement. J Am Coll Cardiol Intv. 2018;11(17):1746. doi: 10.1016/j.jcin.2018.05.042. [DOI] [PubMed] [Google Scholar]
  • 25.Butt JH, Olesen JB, Gundlund A, Kümler T, Olsen PS, et al. Long-term Thromboembolic Risk in Patients with Postoperative Atrial Fibrillation after Left-Sided Heart Valve Surgery. JAMA Cardiol. 2019;4(11):1139–1147. doi: 10.1001/jamacardio.2019.3649. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.El-Chami MF, Kilgo P, Thourani V, Lattouf OM, Delurgio DB, Guyton RA, et al. New-Onset Atrial Fibrillation Predicts Long-Term Mortality After Coronary Artery Bypass Graft. J Am Coll Cardiol. 2010;55(13):1370. doi: 10.1016/j.jacc.2009.10.058. [DOI] [PubMed] [Google Scholar]
  • 27.Yoon Y-H, Ahn J-M, Kang D-Y, Ko E, Lee PH, Lee S-W, et al. Incidence, Predictors, Management, and Clinical Significance of New-Onset Atrial Fibrillation After Transcatheter Aortic Valve Implantation. Am J Cardiol. 2019;123(7):1127. doi: 10.1016/j.amjcard.2018.12.041. [DOI] [PubMed] [Google Scholar]
  • 28.Taha A, Nielsen SJ, Bergfeldt L, Ahlsson A, Friberg L, Björck S, et al. New-onset atrial fibrillation after coronary artery bypass grafting and long-term outcome: A population-based nationwide study from the SWEDEHEART registry. J Am Heart Assoc. 2021;10(1):1–9. doi: 10.1161/JAHA.120.017966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Benedetto U, Gaudino MF, Dimagli A, Gerry S, Gray A, Lees B, et al. Postoperative atrial fibrillation and long-term risk of stroke after isolated coronary artery bypass graft surgery. Circulation. 2020;142(14):1320–1329. doi: 10.1161/CIRCULATIONAHA.120.046940. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Madsen JM, Jacobsen MR, Sabbah M, Topal DG, Jabbari R, Glinge C, et al. Long-term prognostic outcomes and implication of oral anticoagulants in patients with new-onset atrial fibrillation following st-segment elevation myocardial infarction. Am Heart J. 2021;238:89–99. doi: 10.1016/j.ahj.2021.04.012. [DOI] [PubMed] [Google Scholar]
  • 31.Pistoia F, Sacco S, Tiseo C, Degan D, Ornello R, Carolei A. The Epidemiology of Atrial Fibrillation and Stroke. Cardiol Clin. 2016;34(2):255. doi: 10.1016/j.ccl.2015.12.002. [DOI] [PubMed] [Google Scholar]
  • 32.Sanna T, Diener H-C, Passman RS, di Lazzaro V, Bernstein RA, Morillo CA, et al. Cryptogenic Stroke and Underlying Atrial Fibrillation. N Engl J Med. 2014;370(26):2478. doi: 10.1056/NEJMoa1313600. [DOI] [PubMed] [Google Scholar]
  • 33.Jame S, Barnes G. Stroke and thromboembolism prevention in atrial fibrillation. Heart. 2020;106(1):10. doi: 10.1136/heartjnl-2019-314898. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) Eur Heart J. 2021;42(5):546. doi: 10.1093/eurheartj/ehaa612. [DOI] [PubMed] [Google Scholar]
  • 35.Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation. Ann Intern Med. 2007;146(12):857. doi: 10.7326/0003-4819-146-12-200706190-00007. [DOI] [PubMed] [Google Scholar]
  • 36.Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955. doi: 10.1016/S0140-6736(13)62343-0. [DOI] [PubMed] [Google Scholar]
  • 37.de With RR, Marcos EG, Dudink EAMP, Spronk HM, Crijns HJGM, Rienstra M, et al. Atrial fibrillation progression risk factors and associated cardiovascular outcome in well-phenotyped patients: data from the AF-RISK study. EP Europace. 2020;22(3):352. doi: 10.1093/europace/euz339. [DOI] [PubMed] [Google Scholar]
  • 38.Dobrev D, Aguilar M, Heijman J, Guichard J-B, Nattel S. Postoperative atrial fibrillation: mechanisms, manifestations and management. Nat Rev Cardiol. 2019;16(7):417. doi: 10.1038/s41569-019-0166-5. [DOI] [PubMed] [Google Scholar]
  • 39.Lin M-H, Kamel H, Singer DE, Wu Y-L, Lee M, Ovbiagele B. Perioperative/Postoperative Atrial Fibrillation and Risk of Subsequent Stroke and/or Mortality. Stroke. 2019;50(6):1364. doi: 10.1161/STROKEAHA.118.023921. [DOI] [PubMed] [Google Scholar]
  • 40.Perino AC, Fan J, Askari M, Heidenreich PA, Keung E, Raitt MH, et al. Practice Variation in Anticoagulation Prescription and Outcomes After Device-Detected Atrial Fibrillation. Circulation. 2019;139(22):2502. doi: 10.1161/CIRCULATIONAHA.118.038988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Yadava M, Hughey AB, Crawford TC. Postoperative atrial fibrillation: incidence, mechanisms, and clinical correlates. Cardiol Clin. 2014;32(4):627. doi: 10.1016/j.ccl.2014.07.002. [DOI] [PubMed] [Google Scholar]
  • 42.John RM, Michaud GF, Stevenson WG. Atrial fibrillation hospitalization, mortality, and therapy. Eur Heart J. 2018;39(44):3958–3960. doi: 10.1093/eurheartj/ehy622. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

12959_2021_342_MOESM1_ESM.docx (554.1KB, docx)

Additional file 1. Supplementary Methods and Results.

Data Availability Statement

All data generated and analyzed are included in this research article.

Articles from Thrombosis Journal are provided here courtesy of BMC

RESOURCES